Literature DB >> 9195068

The epidemiology of hematogenous candidiasis caused by different Candida species.

D Abi-Said1, E Anaissie, O Uzun, I Raad, H Pinzcowski, S Vartivarian.   

Abstract

The medical records of patients with hematogenous candidiasis at M. D. Anderson Cancer Center (Houston) between 1988 and 1992 were retrospectively reviewed. There were 491 episodes of infection (6 per 1,000 admissions), 79% of which occurred outside the intensive care unit setting. A significant decrease in incidence was observed among patients with leukemia over the study period, together with a relative decrease in Candida albicans and Candida tropicalis infections and an increase in Candida krusei and possibly Candida glabrata infections. In the multivariate analysis, fluconazole prophylaxis provided strong protection against the development of C. tropicalis infection (odds ratio [OR] = 0.08) and C. albicans infection (OR = 0.15), in comparison with protection against infections due to other species, but it was the single most important determinant for the relative increase in C. krusei (OR = 27.07) and C. glabrata (OR = 5.08) infections. In conclusion, there has been a substantial shift in the epidemiology of hematogenous candidiasis caused by different Candida species in recent years. Fluconazole appears to be playing a major role in this observed shift.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9195068     DOI: 10.1086/513663

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  168 in total

1.  Non-albicans Candida species isolated from plastic devices.

Authors:  E Dorko; M Kmet'ová; A Marossy; F Dorko; M Molokácová
Journal:  Mycopathologia       Date:  1999-12       Impact factor: 2.574

2.  Management of Infections Caused by Candida glabrata.

Authors: 
Journal:  Curr Infect Dis Rep       Date:  2000-10       Impact factor: 3.725

3.  Potency of anidulafungin compared to nine other antifungal agents tested against Candida spp., Cryptococcus spp., and Aspergillus spp.: results from the global SENTRY Antimicrobial Surveillance Program (2008).

Authors:  Shawn A Messer; Ronald N Jones; Gary J Moet; Jeffrey T Kirby; Mariana Castanheira
Journal:  J Clin Microbiol       Date:  2010-06-09       Impact factor: 5.948

4.  Emerging Issues in Nosocomial Fungal Infections.

Authors: 
Journal:  Curr Infect Dis Rep       Date:  1999-10       Impact factor: 3.725

5.  Therapeutic Approach to Candida Sepsis.

Authors: 
Journal:  Curr Infect Dis Rep       Date:  1999-08       Impact factor: 3.725

6.  Preliminary evaluation of a semisolid agar antifungal susceptibility test for yeasts and molds.

Authors:  H Provine; S Hadley
Journal:  J Clin Microbiol       Date:  2000-02       Impact factor: 5.948

7.  Caspofungin for prevention of intra-abdominal candidiasis in high-risk surgical patients.

Authors:  Laurence Senn; Philippe Eggimann; Riadh Ksontini; Andres Pascual; Nicolas Demartines; Jacques Bille; Thierry Calandra; Oscar Marchetti
Journal:  Intensive Care Med       Date:  2009-01-27       Impact factor: 17.440

8.  Prospective, multicenter surveillance study of Candida glabrata: fluconazole and itraconazole susceptibility profiles in bloodstream, invasive, and colonizing strains and differences between isolates from three urban teaching hospitals in New York City (Candida Susceptibility Trends Study, 1998 to 1999).

Authors:  Amar Safdar; Vishnu Chaturvedi; Brian S Koll; Davise H Larone; David S Perlin; Donald Armstrong
Journal:  Antimicrob Agents Chemother       Date:  2002-10       Impact factor: 5.191

9.  Risk factors for fluconazole-resistant Candida glabrata bloodstream infections.

Authors:  Ingi Lee; Neil O Fishman; Theoklis E Zaoutis; Knashawn H Morales; Mark G Weiner; Marie Synnestvedt; Irving Nachamkin; Ebbing Lautenbach
Journal:  Arch Intern Med       Date:  2009-02-23

Review 10.  Immunopathogenesis of oropharyngeal candidiasis in human immunodeficiency virus infection.

Authors:  Louis de Repentigny; Daniel Lewandowski; Paul Jolicoeur
Journal:  Clin Microbiol Rev       Date:  2004-10       Impact factor: 26.132

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.